What do lab professionals need to do to ensure sufficient documentation for billing clinical laboratory and pathology services?
Diana Voorhees, MA, MLS(ASCP)SH, CLCP, CPCO
Diana W. Voorhees, MA, MLS(ASCP)SH, CLCP, CPCO, is the CEO/Principal of DV & Associates Inc., Salt Lake City, UT.
Posts by the Author
Labs will have to submit Z-Codes with every molecular pathology testing code billed to UnitedHealthcare, starting Aug. 1.
Recent developments pose reimbursement and compliance challenges for billing and coding infectious disease testing—here’s how to manage them.
The new codes have garnered attention as a future mechanism for additional reimbursement and thus deserve further discussion.
Auditing in medical laboratories is critical for reviewing processes to identify erroneous outcomes, as well as areas for improvement.
Proper usage of ABN-related modifiers is a significant issue that has a direct impact on your lab’s reimbursement and compliance.
It’s imperative for labs to establish and maintain an active corporate compliance program that augments the actual scientific testing.
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
One of the biggest danger areas that labs and their billing staffs face in COVID-19 test reimbursement is improper use of HCPCS code G2023.
What labs and billing managers need to know about multianalyte assays with algorithmic analyses coding for tests based on molecular platforms.